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Summary. We studied the prospect of synergy between the antimicrobial peptide p138c and non-peptide antibiotics for 
increasing the potency and bacterial killing kinetics of these agents. The production of p138c was maximized in the late 
exponential growth phase of Bacillus subtilis CSB138. Purification of p138c resulted in a total of 4800 arbitrary units (AU) with 
19.15-fold and 3.2% recovery. Peptide p138c was thermo-tolerant up to 50 °C and stable at pH 5.8 to 11. The biochemical 
nature of p138c was determined by a bioassay, similar to tricine-SDS-PAGE, indicating inhibition at 3 kDa. The amino acid 
sequence of p138c was Gly-Leu-Glu-Glu-Thr-Val-Tyr-Ile-Tyr-Gly-Ala-Asn-Met-X-Ser. Potency and killing kinetics against 
vancomycin-resistant Staphylococcus aureus improved considerably when p138c was synergized with oxacillin, ampicillin, 
and penicillin G. The minimal inhibitory concentration (MIC) of p138c showed a 4-, 8-, and 16-fold improvement when p138c 
was combined with oxacillin, ampicillin, and penicillin G, respectively. The fractional inhibitory concentration index for the 
combination of p138c and oxacillin, ampicillin, and penicillin G was 0.3125, 0.25, and 0.09, respectively. Synergy with 
non-peptide antibiotics resulted in enhanced killing kinetics of p138c. Hence, the synergy between antimicrobial peptide and 
non-peptide antibiotics may enhance the potency and bacterial killing kinetics, providing more potent and rapidly acting agents 
for therapeutic use. [Int Microbiol 20(1):43-53 (2017)]
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Introduction
The wide use of antibiotics, in the past and recent decades, has 
caused the rapid emergence of antibiotic-resistant bacteria, 
indicating the need for the development of new antimicrobial 
agents. Antimicrobial peptides (AMPs), present in the host im-
mune system, may be a new, anti-infective alternative to con-
ventional antibiotics. Because of their broad-spectrum antimi-
crobial activity and exclusive membrane action mechanism, 
they may replace or accompany conventional antibiotics [26]. 
Therefore, AMPs can be used to develop future antibiotics. To 
date, approximately 1000 naturally occurring antibacterial 
peptides have been isolated. Despite this large number of iso-
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lated peptides, only a few have clinical applications because 
most of them display poor potency, specificity, and in vivo 
stability [5]. These drawbacks of AMPs need to be addressed 
in order to achieve effective development and application of 
new antimicrobial agents for clinical use. Hence, efforts have 
been placed into enhancing the killing kinetics, potency, and 
specificity of antibacterial peptides.
The activity and selectivity of AMPs are driven by their 
charge, amphipathicity, and hydrophobicity [4,25]. To ad-
dress these factors, short AMP derivatives, with cell selective 
toxicity, have been developed to improve the activity and 
specificity based on the amino acid composition, charge, and 
hydrophobicity of natural peptides [10,13,15,21,27]. Toxicity 
has been reduced by minor sequence modifications [2,6,14]; 
however, such approaches are time consuming and costly. 
The use of combination therapy is effective in overcoming 
antibiotic resistance. Employing β-lactamase inhibitors as co-
drugs with conventional antibiotics is well known [11,16]. 
The synergistic effect of antibiotic activity depends on the 
ability of the two molecules to exert a deleterious effect on the 
target microorganism higher than the sum of the effects of 
each drug alone. Synergy reduces the MIC of the combined 
drugs and helps prevent the development of resistance in mi-
croorganisms [16,24].
The widespread use of antibiotics plays a major role in the 
emergence of drug-resistant bacteria. Unhealthy practices in 
the pharmaceutical and manufacturing industries are also like-
ly sources of the emergence of antibiotic-resistant strains [9]. 
Staphylococcus aureus and Enterococcus faecium are the ma-
jor antibiotic-resistant pathogens found in hospitals. Methicil-
lin-resistant Staphylococcus aureus (MRSA), detected for the 
first time in 1961 in Britain, is now common in hospitals. The 
first strain with complete resistance (>16 µg/ml) to vancomy-
cin, termed vancomycin-resistant Staphylococcus aureus 
(VRSA), appeared in the United States in 2002. Vancomycin-
resistant Enterococcus (VRE) was reported in 1987. A report 
in 2004 showed that 9% of nosocomial bloodstream infections 
were caused by enterococci and 2% by the E. faecalis strain 
[23]. This rapid emergence of resistant bacteria highlights the 
need to find alternatives for conventional antibiotics.
In this study, we isolated, identified, and characterized a 
bacterial isolate from fermented food using gene sequencing. 
Further, we studied the possible synergy between the antimi-
crobial peptide and non-peptide antibiotics. We have identi-
fied isolates with promising antimicrobial profiles and evalu-
ated their biological potency. The combination of antimicro-
bial peptide and non-peptide antibiotics showed effective 
synergy, which we evaluated using fractional inhibitory con-
centration (FIC) indices. Our antimicrobial peptide was mod-
erately potent and synergistic with commonly used antibiot-
ics; it also showed robust potency and killing kinetics.
Materials and methods
Materials. This The chemicals and solvents used in our study were of ex-
tra pure grade. Sepharose CL-6B and Sephadex G-50 were obtained from 
Pharmacia (Uppsala, Sweden). All other reagents were of the highest analyti-
cal grade available.
Bacterial strain and production of the antimicrobial pep-
tide. More than 100 fermented food samples were used to isolate the bacte-
rial strain. Isolation was performed according to the method described previ-
ously [16]. Briefly, 1g of the fermented food sample was mixed with 0.85% 
NaCl and incubated for 24 h at 37 °C. Following incubation, the sample was 
serially diluted up to 10−7 in Mueller-Hinton broth. The appropriate colony-
forming units (CFU/ml) were estimated by streaking the dilutions on Muel-
ler-Hinton agar media. The dilution with the required CFU/ml was consid-
ered working stock and maintained in 20% glycerol. The bacterial strain 
CSB138, with potent antimicrobial activity, was selected for further study. 
The identification of the bacterial strain, based on morphological characteris-
tics, was performed according to Bergey’s Manual of Systematic Bacteriolo-
gy. Sequencing analysis of the 16S ribosomal RNA (rRNA) gene was con-
ducted for further identification. Antimicrobial peptide production was per-
formed using a bacterial culture grown in optimized medium for 28 h at 37 °C 
in a rotating incubator at 150 rpm.
Media optimization. Optimization of the culture media for strain 
CSB138 was conducted using various carbon and nitrogen sources, and metal 
ions. The carbon sources included mannitol, starch, fructose, sorbitol, su-
crose, glucose, maltose, and lactose. The nitrogen sources included yeast and 
beef extract, malt, tryptone, peptone, oatmeal, and soymeal. The metal ions 
were Na2HPO4, NaH2PO4, MgSO4, ZnSO4, MgCl2, KH2PO4, FeSO4, NaCl, 
and CaCl2. The influence of carbon sources on the production of the antimi-
crobial compound was assessed using media supplemented with 1% yeast 
extract as a nitrogen source and various carbon sources. Fermentation was 
carried out in 250-ml Erlenmeyer flasks at 150 rpm and 37 °C. The influence 
of nitrogen sources on the production of the antimicrobial compound was 
assessed using a medium supplemented with 1% sorbitol as a carbon source 
and various nitrogen sources. The influence of metal ions on the production 
of the antimicrobial compound was determined using 1% sorbitol, 1% yeast 
extract, and various metal ions. The influence of sorbitol, yeast extract, and 
metal ions on the production of the antimicrobial compound by strain 
CSB138 was determined using different proportions of these supplemented 
compounds. The bacterial strain CSB138, cultured in fully optimized media 
containing 1.25% sorbitol and 1% yeast extract (S-YE), was optimal for the 
production of the antimicrobial compound. The antimicrobial compound, 
produced by strain CSB138, was designated as p138c.
Kinetics of bacterial growth. The S-YE fully optimized medium-
was inoculated with freshly grown Bacillus strain CSB138 and incubated 
at 37 °C. Samples (2 ml) were collected at the interval of 4 h and centrifuged 
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at 10,000 ×g for 15 min. The obtained supernatant was assayed for antimicro-
bial activity. Optical density was recorded spectrophotometrically at 620 nm 
and pH was measured.
Purification of p138c. The seed culture, with the bacterial suspension 
turbidity equivalent to that of 0.5 McFarland standard solutions, was trans-
ferred into the main culture in a 2-liter baffled flask, containing 400 ml 
S-YE media, and incubated at 37 °C and 150 rpm for 28 h. Then, the fer-
mented broth was centrifuged (Hanil Science Industrial, Supra 22K, Korea) 
at 10,000 × g at 6 °C for 15 min. The obtained cell-free supernatant was 
treated with diammonium sulfate at the saturation of 20–100%. The active 
precipitation fraction was recovered using centrifugation at 10,000 × g at 6 °C 
for 45 min, dialyzed with 10 mM/l Tris-HCl (pH 7.5) buffer, and subjected 
to ultrafiltration (Millipore). After ultrafiltration through the molecular 
weight cut-off membranes, the biologically active fraction was loaded onto 
a Sepharose CL-6B column (2.5 × 85 cm) (Pharmacia, Uppsala, Sweden) 
using 10 mM/l Tris-HCl (pH 7.5) buffer. The active fractions, obtained from 
Sepharose CL-6B gel permeation column chromatography, were pooled, 
concentrated, further purified with a Sephadex G-50 column (1.7 × 120 cm) 
(Pharmacia, Uppsala, Sweden) using the same buffering system, and sub-
jected to purity analysis.
Tricine-sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis and bioassay. The concentration of p138c was deter-
mined by the Bradford method [1] using bovine serum albumin (BSA) as the 
standard. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(Tricine-SDS-PAGE) [17] was used to analyze the purity of the antimicrobial 
peptide. The electrophoresed gel was stained with Coomassie brilliant blue 
R-250 and destained with methanol/glacial acetic acid/distilled water (1:1:8, 
v/v/v). The inhibitory activity was assayed according to our previously de-
scribed method [16]. Briefly, the electrophoresed gel was washed several 
times with 50 mM/liter Tris-HCl buffer (pH 7.5) containing 2.5% Triton 
X-100. Afterward, the processed gel was overlaid with 0.6% agar on Mueller-
Hinton medium (Difco, USA) containing the indicator organisms (1.5 × 108 
CFU/ml) and incubated at 37 °C for 12 h.
The N-terminal amino acid sequence. The N-terminal amino acid 
sequence of p138c was determined by Edman degradation using the auto-
matic protein sequencing system model 492cLC (Applied Biosystems, Fos-
ter, CA, USA).
The effects of pH, temperature, proteases, and surfactant 
on p138c. The effect of temperature on the activity of p138c was evalu-
ated by incubating this compound at the temperature of 0, 4, 10, 20, 37, 50, 
60, 70, 80, and 121 °C for 24 h and assessing antimicrobial activity using the 
disc diffusion method. The effect of pH on the activity of p138c was tested by 
adjusting the pH 4.2 to 12.5 using 1 M HCl or 1 M NaOH, respectively, and 
assessing antimicrobial activity. In a separate procedure, 10 ml of cell-free 
supernatant were placed into a sterile Petri dish and exposed to UV light in a 
laminar airflow hood for 5 min; then, antimicrobial activity was examined 
using the disc diffusion method.
The effect of various proteases on the activity of p138c was examined 
using 50 µl of cell-free supernatant incubated for 150 min in the presence 
of 1 mg/ml or 0.1 mg/ml of trypsin, proteinase K, and catalase. Antimicro-
bial activity was determined using the disc diffusion method. In a separate 
experiment, Triton X-100, Tween 20, Tween 80, SDS, NaCl, and urea were 
added to p138c to yield the final concentrations of 1.0, 2.0, and 5.0 mM. 
Untreated p138c and the tested reagents, at their respective concentrations 
in distilled water, were used as controls. All the treated and untreated sam-
ples were incubated at 37 °C for 6 h, after which the antimicrobial activity 
was examined using the disc diffusion method.
Antimicrobial inhibitory spectrum. Antimicrobial activity was de-
termined by the disc diffusion method. A disc of filter paper (8 mm, Toyo 
Roshi Kaisha, Japan), saturated with 40 µl of p138c, was placed on the sur-
face of a Mueller-Hinton agar plate, overlaid with indicator microorganisms, 
and incubated at 37 °C for 24 h. Following incubation, the clear zone of inhi-
bition around the paper disc was measured. Antimicrobial activity, with re-
spect to minimal inhibitory concentration (MIC), was determined according 
to our previous report [16]. Various microorganisms, including Bacillus sub­
tilis ATCC 6633, Enterococcus faecalis ATCC 29212, Mycobacterium smeg­
matis ATCC 9341, methicillin-resistant Staphylococcus aureus 5–3, methicil-
lin-resistant S. aureus 4–5, vancomycin-resistant S. aureus, vancomycin-re-
sistant Enterococci 4, vancomycin-resistant Enterococci 98, vancomycin-re-
sistant Enterococci 89, S. aureus KCTC 1928, Micrococcus luteus ATCC 
9341, Escherichia coli KCTC 1923, Salmonella typhimurium KCTC 1925, 
Pseudomonas aeruginosa KCTC 1637, extended-spectrum beta-lactamase 
V4 (E. coli), and Alcaligenes faecalis ATCC 1004 were used as test microor-
ganisms. Vancomycin and bacitracin were used as reference antibiotics. After 
the inoculation of test organisms (1.5 × 108 CFU/mL), the plates were incu-
bated at 37 °C overnight. Minimum bactericidal concentration (MBC) was 
determined using the broth dilution method. Antimicrobial activity was ex-
pressed in terms of arbitrary units (AU). An AU is defined as the highest dilu-
tion of the sample that produces a zone of inhibition. The reciprocal of the 
dilution was regarded as the titer of antimicrobial activity (AU/ml).
Assessment of antibiotic susceptibility. Susceptibility testing of 
the activity of p138c and various antibiotics (oxacillin [Sigma, USA], ampi-
cillin [Sigma], penicillin G [USB, UK], ciprofloxacin [Sigma], bacitracin 
[USB] and vancomycin [Sigma]) against vancomycin-resistant Staphylococ­
cus aureus (VRSA), vancomycin-resistant Enterococci 4, vancomycin-resis-
tant Enterococci 89, and vancomycin-resistant Enterococci 98 was conducted 
using the broth dilution method for the determination of MIC [22]. The bacte-
rial culture (1.5 × 108 CFU/ml), grown overnight, was suspended in Mueller-
Hinton broth; 100 µl of this suspension was aliquoted into a 96-well tissue 
culture plate (TCP). Various concentrations (0.156-80 µg/ml) of the antimi-
crobial peptide in 10 mM/l Tris-HCl (pH 7.5) buffer, and antibiotics in dis-
tilled water, were added to the suspension. The negative control was main-
tained without the addition of any antibiotics. The TCP was incubated at 37 °C 
in a shaking incubator at 150 rpm. After 12 h of incubation, optical density 
was measured at 620 nm. MIC is defined as the lowest concentration of any 
drug that inhibits the measurable growth of the indicator organism after a 
given incubation. Each experiment was performed in triplicate and repeated 
three times. Minimum bactericidal concentration (MBC) was measured by 
plating the content of the clear well, used in the MIC assessment, onto Mueller-
Hinton agar plates. After the incubation, MBC was determined as the lowest 
concentration that inhibited bacterial growth (99.9%) on the surface of the agar.
Bacterial killing kinetics. The cultures (1.5 × 108 CFU/ml) of vanco-
mycin-resistant Staphylococcus aureus (VRSA), vancomycin-resistant En-
terococci 4 (VRE 4), vancomycin-resistant Enterococci 89 (VRE 89), and 
vancomycin-resistant Enterococci 98 (VRE 98), grown overnight, were di-
luted in Mueller-Hinton broth; antibiotics, along with the antimicrobial pep-
tide p138c, were added to 100 µl of the diluted culture. The mixture was in-
cubated at 37 °C and 150 rpm. The samples were collected at regular inter-
vals, diluted, and plated on Mueller-Hinton agar plates. The plates were incu-
bated at 37 °C for 18 h and the colonies were counted. For synergy assess-
ment, MICs were determined by the addition of 0.5 MIC. 
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The checkerboard dilution assay for the assessment of 
synergy. The assessment of synergy was performed using the checker-
board method [7]. Separate antibiotics, and combinations of two antibiotics, 
were incubated with bacteria to observe the bactericidal effect. The MIC of 
combined antibiotics was calculated using the addition of 0.5 MIC of the 
antimicrobial peptide. The fractional inhibitory concentration (FIC) assay 
was used as the base for synergism. The fractional inhibitory concentration 
index (ΣFIC) was estimated according to our previous method [16]. Briefly, 
ΣFIC = FICA + FICB = (CA/MICA) + (CB/MICB), where MICA and MICB are 
the MICs of drugs A and B, and CA and CB are the concentrations of the 
combined drugs, respectively. The interaction was recorded, according to the 
guidelines provided by the European Committee on Antimicrobial Suscepti-
bility Testing, as follows: FIC index ≤ 0.5 indicated synergy, FIC index > 
0.5–1.0 indicated additive action, FIC index > 1.0 to ˂ 2.0 indicated indiffer-
ence, and FIC index ≥ 2.0 indicated antagonism [3].
Results
Identification of the bacterial strain. Strain 
CSB138 showed morphological resemblance to Bacillus. The 
gene sequencing analysis, obtained by gene sequencing 16S 
rRNA, indicated that the isolate showed the closest identity to 
Bacillus subtilis subsp. inaquosorum KCTC 13429 (accession 
no. AMXN01000021) with pairwise similarity of 99.93 %. 
Based on similarities in morphology and gene sequence, our 
strain was classified as Bacillus subtilis CSB138. A phyloge-
netic tree, constructed from the 16S rRNA gene sequence, is 
shown in Fig.1.
Fig. 1. Phylogenetic tree, based on the complete 16S rRNA gene sequence, showing the relationships between the strain CSB138 and closely 
related taxa of the genus Bacillus. Reference sequences were retrieved from GenBank under the accession number indicated in parentheses 
after the strain name. Numbers of nodes are percentage bootstrap values based on 1000 replications; only values greater than 65 % are shown. 
Bar: 0.005 substitutions per nucleotide position.
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Culture media and production of the antimicro-
bial peptide. Microorganisms require specific biological 
culture media in order to grow under laboratory conditions. 
Bacteria, grown in the laboratory culture media, are designed 
to meet all the requirements necessary for confluent growth. 
However, the production of specific protein viz. antimicrobial 
peptide is based on optimized media. Among the carbon and 
nitrogen sources tested, sorbitol and yeast extract, respective-
ly, were more effective. Metal ions did not significantly affect 
the production of p138c. Hence, the optimal medium that we 
used was supplemented with 1.25% sorbitol and 1% yeast ex-
tract (S-YE). The Bacillus isolate CSB138, producing p138c, 
was grown on S-YE medium at 37 °C for 28 h and 150 rpm. 
 
Spectra of p138c. In the growth kinetics study, the maxi-
mal activity of p138c was observed after 28 h in the S-YE 
broth. The initial pH of the broth was 6.25. The activity of 
p138c was detected starting at 4 h at pH 6.34, and maximal 
activity was recorded after 28 h at pH 7.1. The changes in the 
pH of the culture, from 6.25 to 8.38, were observed for up to 60 
h of growth. We recorded increases in the cell density of the 
cultures at OD 620 nm, in the pH range of 6.34 to 8.36, with 
maximal density at pH 8.01 and maximal activity at 7.1. In this 
study, we evaluated the activity of p138c against various micro-
organisms. The antimicrobial activity of p138c was evaluated 
along with the standard reference antibiotics viz. vancomycin 
and bacitracin. The antimicrobial spectrum of p138c was 4 to 
> 8 times greater than that of bacitracin, and > 4 to > 8 times 
more effective than that of vancomycin, against vancomycin-
resistant Staphylococcus aureus and various VREs (Table 1). 
Size exclusion chromatography and molecular 
weight determination of p138c. At the third step of 
purification, the biologically active sample was loaded onto a 
Table 1. Minimum inhibitory concentration of peptide p138c
Antimicrobial spectrum of p138c
MIC (µg/ml) MBC (µg/ml)
p138c Bacitracin Vancomycin p138c
Gram-negative bacteria
Alcaligenes faecalis ATCC 1004 >80 >80 >80 >1280
Escherichia coli KCTC 1923 >80 >80 >80 >1280
Extended-spectrum beta-lactamase V4 (Escherichia coli) >80 >80 >80 >1280
Pseudomonas aeruginosa KCTC 1637 >80 >80 >80 >1280
Salmonella typhimurium KCTC 1925 >80 >80 >80 >1280
Gram-positive bacteria
Bacillus subtilis ATCC 6633 >80 20 0.312 640
Enterococcus faecalis ATCC 29212 2.5 5 2.5 160
Methicillin-resistant Staphylococcus aureus 4-5 0.625 2.5 0.625 640
Methicillin-resistant Staphylococcus aureus 5-3 0.625 2.5 1.25 640
Micrococcus luteus ATCC 9341 80 40 2.5 320
Mycobacterium smegmatis ATCC 9341 40 80 2.5 >1280
Staphylococcus aureus KCTC 1928 20 40 1.25 320
Vancomycin-resistant Staphylococcus aureus 20 80 >80 640
Vancomycin-resistant Enterococci 4 10 40 >80 160
Vancomycin-resistant Enterococci 89 10 >80 >80 640
Vancomycin-resistant Enterococci 98 10 >80 >80 640
MIC, minimum inhibitory concentration; MBC, minimum bactericidal concentration
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Sepharose CL-6B and fractionated at the elution rate of 0.25 
ml per min; the fraction eluted between 590 to 660 min showed 
maximal activity (Fig. 2). The biologically active fractions 
were collected and loaded onto Sephadex G-50 using the same 
buffering system. The active fractions were pooled together 
and desalted using a Sephadex G-25 column. The protein pro-
file was determined using tricine SDS-PAGE, which showed 
a single protein band near 3 kDa. The inhibitory activity of 
p138c was examined in situ. Using an indicator microorgan-
ism, a clear zone of lysis was observed near 3 kDa. Purifica-
tion resulted in a total of approximately 4800 AU with 19.15-
fold overall purification and recovery of 3.2% (Table 2).
Characterization. Residual activity was determined ac-
cording to the retained biological activity. The activity of 
p138c was retained at 100% after heating at temperatures as 
high as 50 °C. Complete loss of activity occurred after heating 
at 121 °C and 105 kPa for 15 min. Peptide p138c tolerated a 
wide range of pH values (5.8 to 11). This ability to retain ac-
tivity over a wide range of pH values may be the result of the 
reversible denaturation of the protein. The effects of tempera-
ture and pH on the activity of p138c are shown in Fig. 3. The 
Fig. 2. Elution profile of peptide p138c from the Sepharose-CL-6B column (2.5 × 85 cm). The column was pre-equilibrated with 10 mM/l 
Tris/HCl buffer (pH 7.5). 
Table 2. Purification of peptide p138c
Steps Total protein (mg) Total activity (AU) Specific activity (AU/mg) Purification fold Recovery %
Crude 308.56 150000 486.12 1 100
Ammonium sulfate pallet 91.59 73600 803.60 1.65 49.1
Sepharose CL-6B 5.79 12000 2071.88 4.26 8
Sephadex G-50 0.52 4800 9310.50 19.15 3.2
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antimicrobial activity of p138c was completely inactivated 
after the cell-free supernatant was treated with proteinase K. 
The effect of trypsin was not detectable, indicating the pro-
teinaceous nature of our antimicrobial peptide. Generally, an-
timicrobial peptides have proteinaceous characteristics. Our 
results show that H2O2 was not the factor responsible for the 
inhibition because no change in activity was recorded when 
p138c was treated with catalase. Peptide p138c was found to 
be sensitive to treatment with SDS, Tween 80, and NaCl; 
however, treatment with Triton X-100, Tween 20, and urea 
had no effect on the antimicrobial activity of p138c. UV treat-
ment did not affect the antimicrobial activity, possibly be-
cause of the proteinaceous nature of p138c. The effects of 
enzymes, detergents, other reagents, and UV- light on the ac-
tivity of p138c are shown in Table 3. 
Amino acid sequence. The N-terminal sequence of the 
last 15 amino acids of p138c was determined to be Gly-Leu-
Glu-Glu-Thr-Val-Tyr-Ile-Tyr-Gly-Ala-Asn-Met-X-Ser. This 
sequence did not show significant homology with those of pep-
tides of similar origin. No full query is covered during the 
search. Searching the National Centre for Biotechnology Infor-
mation (NCBI) protein database using BLAST showed some 
similarity with other protein sequences from the Bacillus sp. 
(Table 4). 
Synergy between p138c and conventional an-
tibiotics. The antimicrobial activity of p138c, determined 
in terms of MIC, was moderately active against gram-positive 
bacteria (MIC of 0.625–80 µg/ml). The antimicrobial spec-
trum of p138c possessed more potency than those of the com-
monly used bacitracin and vancomycin. Peptide p138c showed 
higher antibacterial activity against vancomycin-resistant 
Staphy lo coccus aureus (MIC of 20 µg/ml, 4-fold greater than 
bacitracin and > 4-fold greater than vancomycin, and MBC of 
640 µg/ml), vancomycin-resistant Enterococci 4 (MIC of 10 µg/
ml, 4-fold greater than bacitracin and > 8-fold greater than vanco-
mycin, and MBC of 160 µg/ml), vancomycin-resistant Entero-
cocci 89 (MIC of 10 µg/ml, > 8-fold greater than bacitracin and 
vancomycin, and MBC of 640 µg/ml), and vancomycin-resistant 
Enterococci 98 (MIC of 10 µg/ml, > 8-fold greater than bacitracin 
and vancomycin, and MBC of 640 µg/ml). The synergy between 
p138c and six conventional antibiotics was tested in vitro by 
the checkerboard dilution assay against VRSA and three van-
comycin-resistant isolates of Enterococci (Table 5). Each 
combination of the drugs was assigned a ΣFIC. FIC indices 
Table 3. Effect of proteases, detergents, UV, and other reagents on the 
activity of p138c
Proteases Trypsin ND
Proteinase K  +
Catalase  −
Detergents SDS  +
Triton X-100  −
Tween 20  −
Tween 80  +
NaCl and urea NaCl  +
Urea  −
UV UV-light  −
ND: non-detectable; + inactivation by treatment; − resistant to treatment
Fig. 3. Effect of pH (A) and temperature (B) on the activity of peptide p138c.
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≤ 0.5 were regarded as synergistic. Peptide p138c showed 
synergy with the three β-lactam antibiotics (oxacillin, ampi-
cillin, and penicillin G) used for inhibiting bacterial growth 
(VRSA). p138c, combined with oxacillin or ampicillin, or 
with penicillin G, substantially enhanced the potency of the 
combinatorial effect. The antibacterial activity of combined 
treatment with oxacillin and p138c against VRSA was 4-fold 
greater than that of p138c alone. Similarly, combining p138c 
with ampicillin produced antimicrobial activity that was 
8-fold greater than that of p138c alone; the antimicrobial ac-
tivity of p138c, combined with penicillin G, was 16-fold 
greater than that of p138c alone. These results show that syn-
ergizing p138c with β-lactam antibiotics is an effective strat-
egy for improving antibacterial potency and cost effectiveness 
of antimicrobial peptides. 
Effect of synergy on bactericidal activity. Drugs 
are categorized into bacteriostatic and bactericidal agents 
based on their effectiveness against infectious microorgan-
isms. Bacteriostatic drugs inhibit the growth of bacteria, 
whereas bactericidal drugs kill them. We evaluated the mini-
mum bactericidal concentration of the synergistic combination 
of p138c (MBC, 640 µg/ml) and oxacillin (MBC, 80 µg/ml), 
p138c (MBC, 640 µg/ml) and ampicillin (MBC, 20 µg/ml), and 
p138c (MBC, 640 µg/ml) and penicillin G (MBC, 40 µg/ml) 
against vancomycin-resistant Staphylococcus aureus. The 
combination of p138c (combined MBC, 160 µg/ml) and oxa-
cillin (combined MBC, 5 µg/ml), p138c (combined MBC, 80 
µg/ml) and ampicillin (combined MBC, 2.5 µg/ml), and 
p138c (combined MBC, 80 µg/ml) and penicillin G (com-
bined MBC, 1.25 µg/ml) were bactericidal. The fractional in-
hibitory concentration (FIC) index for the combination of 
p138c and oxacillin was low (0.3125). Similarly, the FIC in-
dex for the combination of p138c and ampicillin was 0.25 and 
that of p138c and penicillin G was 0.09. FIC indices ˂ 0.5 
indicate a strong synergy with respect to bactericidal activity. 
Thus, oxacillin, ampicillin, or penicillin G potentiates bacteri-
cidal activity, demonstrating 4 to 8-fold improvement in the 
bactericidal action of p138c. Our results indicate that synergy 
with conventional antibiotics can transform a moderately bac-
teriostatic agent into a potent bactericidal drug. 
The effect of synergy on bacterial killing ki-
netics. The bacterial load clearance in patients corresponds 
with how well antibiotics perform in killing the targeted bac-
terium. We tested the synergistic effect of p138c (MIC of 20 
µg/ml) and various commonly used conventional antibiotics 
(oxacillin, MIC of 80 µg/ml; ampicillin, MIC of 20 µg/ml; 
and penicillin G, MIC of 40 µg/ml) against vancomycin-resis-
tant Staphylococcus aureus to find a synergistic combination 
of the peptide and non-peptide antibiotics that affected the 
rate of bacterial killing kinetics. Peptide p138c alone was 
largely bacteriostatic against VRSA; in synergy with various 
tested antibiotics, p138c showed improved potency and more 
rapid killing kinetics (Fig. 4). Synergizing the peptide with 
commonly used antibiotics improved the potency of the anti-
microbial peptide and the rate of bacterial killing kinetics.
Discussion
Peptide p138c, produced by Bacillus subtilis CSB138, was 
isolated from fermented food. According to Selhub et al. 
[18], the relationship between bioactive compounds in fer-
mented food and fermentation-enriched chemicals affects the 
profile of the human intestinal microbiota, indicating that the 
Table 4. Comparison of N-terminal amino acid sequence of peptide p138c with other related proteins from the Bacillus sp.
SN Alignment Identity Peptide or protein References
1 GLEETVYIYGANMXS 100 % p138c [Bacillus subtilis] Current study
2 EET+Y YGA  EETIYFYGA 78 % peptidase M16 [Bacillus subtilis]
NCBI Reference Sequence: 
WP_060399736.1
3
+ET YIY GA
DETRYIYTGA 70 % peptidase M20 [Bacillus subtilis] NCBI Reference Sequence: 
WP_060399755.1
4
+ET YIY GA
DETRYIYTGA 70 % protein RocB [Bacillus subtilis] NCBI Reference Sequence: 
WP_003235954.1
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food, was identified via morphological and 16S rRNA gene 
sequencing analyses. p138c can be produced in inexpensive 
optimized culture media (S-YE). Generally, bacteriocin-like 
substances are produced in complex media [12]. The purifica-
tion of p138c was conducted using sequential gel filtration, 
resulting in the eluted compound that was free of unwanted 
proteins and possessing robust antimicrobial activity. The pu-
rification of p138c, using precipitation in the presence of a 
low saturation of diammonium sulfate, and elution at void 
volume using gel permeation chromatography, indicated that 
p138c was secreted in the form of large aggregates. This result 
is consistent with those of other studies examining [8,16]. 
Peptide p138c was purified 19.15-fold with 3.2% recovery. 
Bacterial growth kinetics and inhibitory activity indicated that 
antimicrobial activity occurred during the steady state of the 
growth curve, from early to late stationary phase, and declined 
in the very late stationary phase. Antimicrobial activity of the 
purified product from fermented food may alter the pre-con-
sumption of dietary products. This ultimately amends the ac-
tion by which fermentation-enriched chemicals act on the 
human intestinal microbiota. It is known that the antimicro-
bial peptides have functional activities including antimuta-
genic, anticancer, immunomodulatory, antiatherosclerotic, 
and anti-obesity effects. In our study, p138c inhibited a wide 
spectrum of bacteria and demonstrated antagonistic potential. 
The lower potency, instability, and high production cost of 
antimicrobial peptides have caused major hurdles in their 
clinical development [5]. One of the solutions to these issues 
is synergizing antimicrobial peptides with conventional anti-
biotics, thereby lowering the dosage of each molecule in the 
synergistic combination.
Our study was designed to characterize p138c and study 
the prospect of synergy between the antimicrobial peptide and 
non-peptide antibiotics. The strain, isolated from fermented 
Table 5. Fractional inhibitory concentration (FIC) of peptide p138c
Tested compounds Strains MIC of p138c (µg/ml) MIC in combination with 
p138c (µg/ml)
EFIC Interpretation
Oxacillin (OXA)
VRSA 20 5 0.31 Synergy
VRE 4 10 5 0.63
VRE 89 10 10 <1.125
VRE 98 10 5 0.56
Ampicillin (AMP)
VRSA 20 2.5 0.25 Synergy
VRE 4 10 2.5 0.50 Synergy
VRE 89 10 5 0.63
VRE 98 10 5 0.75
Penicillin G (PENG)
VRSA 20 1.25 0.09 Synergy
VRE 4 10 5 0.75
VRE 89 10 10 1.50
VRE 98 10 5 0.63
Ciprofloxacin (CIP)
VRSA 20 5 2.25
VRE 4 10 5 1.50
VRE 89 10 5 4.50
VRE 98 10 2.5 1.25
Bacitracin (BAC)
VRSA 20 >80 >5
VRE 4 10 80 10
VRE 89 10 80 <9
VRE 98 10 >80 >9
Vancomycin (VAN)
VRSA 20 >80 >5
VRE 4 10 >80 >9
VRE 89 10 >80 >9
VRE 98 10 >80 >9  
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test strain was detected in the mid-stationary phase, attaining 
maximum in the late exponential phase with significant de-
crease at 44 h of incubation. Our results suggest that sporula-
tion had no effect on the production of the antimicrobial com-
pound.
Peptide p138c was found to be stable at a temperature as 
high as 50 °C and a wide range of pH values (5.8–11). Our 
result is comparable to, and shows an even wider pH range 
than those in other studies [8,16,19]. Antimicrobial activity 
was retained over a wide range of pH values, which may be 
due to the reversible denaturation of the protein. Peptide 
p138c was completely inactivated in presence of proteinase 
K, but this effect was not detected after treatment with trypsin, 
indicating the proteinaceous nature of p138c. Neither H2O2 
nor UV light had any effect on the activity of p138c, again 
indicating the proteinaceous property of our antimicrobial 
peptide. The N-terminal amino acid sequence analysis of 
p138c was performed using automated Edman degradation. 
Among the last 15 N-terminal amino acids in the sequence, 
one residue, which could not be identified, is shown as X. 
During the sequencing cycles of the analysis, the reaction was 
not blocked. The unknown residue in the amino-acid sequence 
may be the result of uncleaved amino acids.
Synergizing antimicrobial peptides and non-peptide anti-
biotics is an efficient approach for lowering the dosage of 
each molecule in combinatorial therapy. Our study showed an 
improvement in the MICs of p138c combined with oxacillin, 
ampicillin, and penicillin G. Synergy was indicated when FIC 
indices were ≤ 0.5. p138c, along with oxacillin, ampicillin, or 
penicillin G, caused dramatic decreases in MIC. The observed 
potentiation of antibacterial activity against VRSA was 4-fold 
greater when p138c was combined with oxacillin, 8-fold 
greater when p138c was combined with ampicillin, and 16-
fold greater when p138c was combined with penicillin G. The 
effectiveness of synergy can be evaluated by an effective uti-
lization of a weak or moderately effective antimicrobial pep-
tide, which, if used independently, would be considered a 
poor antibiotic. These combinations influence the antibiotic 
potency of the peptide-nonpeptide effect and decrease the 
dose of each agent in the drug combination, rendering syner-
gy more economical. In our study, the synergy of the peptide 
with three β-lactam antibiotics (oxacillin, ampicillin, and pen-
icillin G) suggested that the antimicrobial peptide might be 
synergistic with other antibiotics. Our results indicate that 
synergy could potentiate the bacteriostatic effect and improve 
bactericidal potency. In synergy with oxacillin, ampicillin, or 
penicillin G, the bactericidal potency increased 4 to 8-fold, 
demonstrating a potent bactericidal combination. According 
to Stratton, bactericidal drugs are preferable to bacteriostatic 
drugs because the risk for emergence of a resistant mutant is 
very low; the development of resistant mutants is prevented 
by killing the microorganism [20]. Hence, we can reduce the 
chances of antibiotic resistance by increasing the bactericidal 
potency of antimicrobial peptides. In addition to high poten-
cy, rapid killing kinetics are among the properties of antibio-
tics. In this study, the synergistic activity of oxacillin (MIC of 
Fig. 4. Synergy improves killing kinetics of p138c. Killing kinetics of 
p138c, and of p138c combined with oxacillin (A), ampicillin (B), and 
penicillin G (C), with added 0.5 MIC of p138c, against vancomycin-resistant 
Staphylococcus aureus (VRSA).
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80 µg/ml), ampicillin (MIC of 20 µg/ml), and penicillin G 
(MIC of 40 µg/ml), combined with p138c (MIC of 20 µg/ml), 
against VRSA showed a robust improvement in potency (Fig. 4). 
As shown in this figure, p138c alone was largely bacteriostatic 
against VRSA, but in synergy with the three β-lactam anti-
biotics, p138c showed improved potency and killing kinetics.
In summary, our study investigated the potency and bacte-
rial killing kinetics of the antimicrobial peptide p138c syner-
gized with conventional antibiotics. The results of our study 
highlight the use of synergy to enhance the therapeutic poten-
tial of antimicrobial peptides. These strategies can be applied 
to a wide spectrum of antimicrobial peptides to produce a 
suitable agent for the treatment of MDR infections. 
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